In addition, tirzepatide affects certain chemicals in the brain which in turn decreases appetite, increases energy expenditure, and prevents ectopic fat deposition (abnormal fat accumulation in body parts that normally contains small amounts of fat)
The FDA cannot reliably determine how often this side effect occurs or if the drug actually caused the ileus due to the voluntary nature of the reports
That changed in 2023, when the FDA determined that 19 peptides posed significant safety risks and moved them to a de facto do not compound list
From patents to progress: unraveling gout's journey through clinical trials and advancements
The choice of liraglutide was substantiated by its favorable pharmacokinetic profile in patients with impaired kidney function and therefore by its increasing clinical use in this population 12
International Journal of Environmental Research and Public Health, 18(11), 5533